Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: J&J points to medtech dip, Novartis lobs MS grenade to Teva

This article was originally published in Scrip

Executive Summary

Second-quarter earnings season kicked off properly this week with the world's largest healthcare company, Johnson & Johnson, reporting (scripintelligence.com, 16 July 2013). The healthcare conglomerate commonly known as J&J has a market capitalisation of nearly $260bn and is so diverse that it provides a window into other pure-play pharmaceutical, consumer, medical device and diagnostic companies, as well as a number of specific drugs, the revenues on which, much smaller companies are dependent.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022187

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel